Finn, Warnke & Gayton
Download your FREE report today!
Unlocking Intellectual Property Assets. The Key? Sealed Bid sale.
Download Now!
 6/29/2009   Assets sold
 6/22/2009 Link Prospect Therapeutics Inc.'s GCS-100 Has Focused on Developing Treatment for Thr More ...
 6/15/2009 Link Prospect Therapeutics' In Vitro Studies Demonstrate that GCS-100 Drug Binds to a More ...
 6/5/2009 Link Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Conc More ...
 5/26/2009 Prospect Therapeutics Press Release 05_26_09.pdf Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation in a Vari More ...
 5/19/2009 Prospect Therapeutics, Inc. 05_19_09.pdf Prospect Therapeutics, Inc.'s GCS-100 Exhibits a Low Toxicity Profile in Cancer More ...
 5/12/2009 Prospect Therapeutics Assigns All Its Assets to JFFinn_05_12_09.pdf Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A More ...
 5/7/2009  Prospect Therapeutics Assigns Assets to Joseph F. Finn, Jr. C.P.A. for the Benef More ...
 6/1/2009 Link Interim Phase 2 Results On Prospect Therapeutics' GCS-100 Presented At The 10th More ...
Finn, Warnke and Gayton • 27 Heckle St - Suite 100 • Wellesley, Massachusetts 02481 • 781-237-8840
© Copyright 2013, Finn, Warnke & Gayton All rights reserved.